I allocated 5 cr to Plazza as a strategic investment in a B2B quick‑commerce platform for pharma.
The decision was driven by a strong data moat—real‑time insights for manufacturers like Cipla and Abbott—combined with the urgent need for minutes‑level fulfillment, a broken retail experience compared to U.S. CVS, and the opportunity to launch private‑label generics. The founding team’s deep quick‑commerce expertise further reinforced the investment thesis.
In pharma, data itself is as valuable as distribution.
When you fall sick, you don’t want next‑day delivery: you want your prescription fulfilled within minutes.
I decided to partner with Plazza to build a “Blinkit for Medicines”, leveraging their real‑time transaction data and quick‑commerce expertise to give manufacturers like Cipla and Abbott visibility at scale and to shrink fulfillment from next‑day to minutes.
I backed Plazza, a pharma‑focused q‑commerce startup that built a dedicated fulfillment engine to tackle licensing, cold‑storage, and city‑level SKU variability.
Plazza went from a 4Cr pre seed to a ~150Cr Series A in under a year.
The reason fulfilment rates sit far above the industry norm.